Company intelligence / Profile preview

Vivozon

Hwaseong, Gyeonggi, South Koreavivozon.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Vivozon’s lead candidate, VVZ-149 (Opiranserin), discovered via its multi-target platform, has advanced to global Phase 3 clinical trials. The company emphasizes rapid and efficient drug discovery for pain and CNS indications using its proprietary technology. It has received US FDA fast track designation for at least one program.

Therapeutic areas: Neurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

6 assets

VVZ-2471

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vivozon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivozon.

Explore the full profile